v3.26.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
AbbVie Stock Purchase Agreement
At-The-Market Offerings
Follow-on offering
Common Stock
Common Stock
AbbVie Stock Purchase Agreement
Common Stock
At-The-Market Offerings
Additional Paid-in Capital
Additional Paid-in Capital
AbbVie Stock Purchase Agreement
Additional Paid-in Capital
At-The-Market Offerings
Additional Paid-in Capital
Follow-on offering
Additional Paid-in Capital
follow-on public offering
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ 17,598             $ 401,351         $ (383,753)
Beginning balance (in shares) at Dec. 31, 2024         3,268,299                
Stockholders' Deficit                          
Issuance of common stock, net of issuance costs (in shares)           310,559 110,747            
Issuance of common stock, net of issuance costs 2,017 $ 2,810             $ 2,810 $ 2,017      
Issuance of common stock and prefunded warrants, net of issuance costs       $ 10,818             $ 10,818    
Issuance of common stock under employee stock purchase plan 40             40          
Issuance of common stock under employee stock purchase plan (in shares)         3,240                
Vesting of restricted common stock (in shares)         7,952                
Exercise of stock options 9             9          
Exercise of stock options (in shares)         1,155                
Stock-based compensation expense 2,886             2,886          
Net loss (29,109)                       (29,109)
Ending balance at Jun. 30, 2025 7,069             419,931         (412,862)
Ending balance (in shares) at Jun. 30, 2025         3,701,952                
Beginning balance at Mar. 31, 2025 10,700             407,718         (397,018)
Beginning balance (in shares) at Mar. 31, 2025         3,698,205                
Stockholders' Deficit                          
Issuance of common stock and prefunded warrants, net of issuance costs 10,818                     $ 10,818  
Issuance of common stock under employee stock purchase plan 40             40          
Issuance of common stock under employee stock purchase plan (in shares)         3,240                
Exercise of stock options 4             4          
Exercise of stock options (in shares)         507                
Stock-based compensation expense 1,351             1,351          
Net loss (15,844)                       (15,844)
Ending balance at Jun. 30, 2025 7,069             419,931         (412,862)
Ending balance (in shares) at Jun. 30, 2025         3,701,952                
Beginning balance at Dec. 31, 2025 35,273             454,062         (418,789)
Beginning balance (in shares) at Dec. 31, 2025         4,530,641                
Stockholders' Deficit                          
Issuance of common stock, net of issuance costs (in shares)             592,300            
Issuance of common stock, net of issuance costs 4,458                 4,458      
Issuance of common stock and prefunded warrants, net of issuance costs       $ 37,256             $ 37,256    
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)         735,909                
Issuance of common stock under employee stock purchase plan 36             36          
Issuance of common stock under employee stock purchase plan (in shares)         4,973                
Issuance of common stock to settle the liabilities to issue common stock 7,333       $ 1     7,332          
Issuance of common stock to settle liabilities to issue common stock (in shares)         708,223                
Issuance of common stock in connection with the exercise of prefunded warrants (in shares)         735,909                
Vesting of restricted common stock (in shares)         7,952                
Exercise of stock options $ 1             1          
Exercise of stock options (in shares) 151       151                
Stock-based compensation expense $ 3,809             3,809          
Net loss (15,902)                       (15,902)
Ending balance at Jun. 30, 2026 72,264       $ 1     506,954         (434,691)
Ending balance (in shares) at Jun. 30, 2026         6,580,149                
Beginning balance at Mar. 31, 2026 $ 72,545       $ 1     500,862         (428,318)
Beginning balance (in shares) at Mar. 31, 2026         5,782,536                
Stockholders' Deficit                          
Issuance of common stock, net of issuance costs (in shares) 592,300           592,300            
Issuance of common stock and prefunded warrants, net of issuance costs     $ 4,458             $ 4,458      
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)         200,298                
Issuance of common stock under employee stock purchase plan $ 36             36          
Issuance of common stock under employee stock purchase plan (in shares)         4,973                
Issuance of common stock in connection with the exercise of prefunded warrants (in shares)         200,298                
Exercise of stock options (in shares)         42                
Stock-based compensation expense 1,598             1,598          
Net loss (6,373)                       (6,373)
Ending balance at Jun. 30, 2026 $ 72,264       $ 1     $ 506,954         $ (434,691)
Ending balance (in shares) at Jun. 30, 2026         6,580,149